1. Introduction {#s0005}
===============

Reduced uptake of \[^18^F\]‑2‑fluoro‑2‑deoxy‑[d]{.smallcaps}‑glucose (\[^18^F\]FDG) in the posterior cingulate cortex (PCC) is a characteristic feature of Alzheimer\'s disease (AD)([@bb0055]; [@bb0070]; [@bb0075]; [@bb0100]). However, PCC hypometabolism may not be restricted to AD and can also be seen in other dementias such as the behavioural variant of frontotemporal dementia (bvFTD), which is characterized by most prominent hypometabolism in the frontal lobe ([@bb0025]). Previous studies reported inconsistent findings regarding involvement of the PCC in bvFTD, and involvement of the PCC mostly coincided with more advanced stages of the disease ([@bb0010]; [@bb0030]; [@bb0060]; [@bb0070]; [@bb0150]). Little is known about the prevalence of PCC hypometabolism at time of bvFTD diagnosis, nor about its association with clinical phenotype. The aim of this study was therefore to assess the prevalence of PCC hypometabolism in AD, bvFTD, and cognitive normal (CN) subjects using visual reading. A second objective was to explore associations between PCC standard uptake value ratio (SUVr; using both cerebellum and pons as reference regions) and clinical characteristics.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

A total of 136 subjects from the Amsterdam dementia cohort were included([@bb0140]). AD subjects (n = 81) met clinical criteria for probable AD and had CSF tau/Aβ~1--42~ \> 0.52, implying high likelihood for underlying AD pathology ([@bb0035]; [@bb0085]). BvFTD subjects (n = 33) met clinical criteria for probable bvFTD and diagnosis was confirmed by a neurologist specialised in bvFTD (YP) ([@bb0120]). Furthermore, all bvFTD patients had CSF Aβ~1--42~ \> 550 pg/mL, implying a low likelihood for underlying amyloid pathology ([@bb0105]). CN subjects (n = 22) performed normally on an extensive neuropsychological test battery, and showed no abnormalities on MRI indicative of underlying neurodegeneration, as evaluated by an experienced neuroradiologist (FB). All CN subjects had CSF tau/Aβ~1--42~ \< 0.52, implying a low likelihood for underlying AD pathology ([@bb0035]). The local Medical Ethics Review Committee approved the study. All subjects provided written informed consent prior to inclusion.

2.2. Neuropsychological assessment {#s0020}
----------------------------------

A standard neuropsychological test battery was used to assess major cognitive functions ([@bb0140]). Test scores were transformed into z-scores, and inverted where appropriate, so that higher scores represented better performances. Compound scores were calculated for each cognitive domain investigated. In addition, Mini-Mental State Examination (MMSE), Clinical Dementia Rating scale (CDR), and Neuropsychiatric Inventory (NPI) were included.

2.3. APOE genotype and CSF biomarkers {#s0025}
-------------------------------------

Collection and analysis of APOE genotype and CSF biomarkers were performed as described previously ([@bb0140]). For inclusion of bvFTD subjects, the cut-off for normal CSF Aβ~1--42~ was set at \>550 pg/mL. For inclusion of AD patients, the cut-off for abnormal CSF tau/Aβ~1--42~ was set at \>0.52, and for CN subjects \<0.52 ([@bb0035]). Finally, associations between CSF biomarkers and PCC SUVr were assessed using continuous variables.

2.4. MRI protocol {#s0030}
-----------------

T1-weighted 3D MPRAGE images were acquired for co-registration, segmentation, and region of interest definition. Images were obtained on a 1.5 T Sonata scanner (Siemens, Erlangen, Germany; slice thickness 1.5 mm, 160 slices, matrix size 256 × 256, voxel size 1 × 1 × 1.5 mm, echo time 3.97 ms, repetition time 2700 ms, flip angle 8°) or a 3 T SignaHDxt scanner (General Electric, Milwaukee, Wisconsin, USA; slice thickness 1 mm, 180 slices, matrix size 256 × 256, voxel size 1x1x1.5 mm, echo time 3 ms, repetition time 708 ms, flip angle 12°).

2.5. PET protocol {#s0035}
-----------------

Prior to injection of \~185 MBq \[^18^F\]FDG, patients were required to rest for 10 min with eyes closed and earplugs in a dimly lit room. \[^18^F\]FDG PET emission scans were acquired at 45 min post injection using either an ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN) or a Gemini TF-64 PET/CT (Philips, Best, The Netherlands) scanner. In addition, in case of the HR+, a 10 min transmission scan or, in case of the Gemini, a low dose CT scan was acquired prior to the emission scan to correct emission data for tissue attenuation. Image acquisition, pre-processing and the reconstruction protocol have been described elsewhere ([@bb0145]).

2.6. Imaging analysis {#s0040}
---------------------

T1 weighted MR images were co-registered to corresponding \[^18^F\]FDG PET data using the Vinci software package (version 2.56.0). Using PVElab together with the Hammers template, regions of interest (ROI) were delineated on the MRI scans and superimposed onto the dynamic PET scan to generate regional time activity curves (TAC). ([@bb0045]; [@bb0135]) Since the pons is not a standard region in this template, it was delineated manually on the co-registered T1w MR image using in-house built software in IDL, and superimposed onto the dynamic PET images. The manual delineation was performed based on voxel intensity differences between the pons and the remaining part of the brainstem on the T1w MR image. Using SPM segmentation, pons white matter volumes were extracted from which a 95% CI of pons white matter volume was calculated for quality insurance of the manual delineation. Outliers were checked on both their delineation and segmentation, and when necessary corrected. PCC SUVr was calculated as PCC to reference region ratio, by dividing the images by the reference region value. For the reference tissue cerebellum grey matter (further referred to as 'cerebellum') and pons white matter (further referred to as 'pons') TACs were assessed separately.

Two nuclear medicine physicians, blinded for clinical diagnosis, performed visual reading. The level of experience in visual reading of \[^18^F\]FDG brain images differed between readers. Reader A was very experienced, reading multiple \[^18^F\]FDG images weekly, whilst reader B recently completed training to be nuclear medicine physician. PCC hypometabolism was considered to be present when the PCC (defined using anatomical boundaries that are described elsewhere ([@bb0090])) was isointense -- since healthy brain metabolism is associated with highest glucose uptake in the PCC ([@bb0080]) -- or hypointense compared with other cortical regions by thresholding the SUVr image to identify the area in the brain with the highest activity concentration ([@bb0100]).

2.7. Statistical analyses {#s0045}
-------------------------

Statistical analyses were performed using SPSS for Windows version 22.0 (IBM Corp. Armonk, NY). Clinical characteristics were compared between diagnostic groups (AD, bvFTD and CN) using chi-square tests (sex, APOE genotype), Kruskal-Wallis analyses (education, duration of complaints, MMSE, CDR, and NPI), or analysis of variance (ANOVA) with post hoc Bonferroni analyses (SUVr, age, age at onset of complaints, CSF biomarkers, neuropsychological compound z-scores). When group differences were observed with chi-squared tests or Kruskal-Wallis analyses, ANOVA with Tamhane\'s T2 post hoc analyses was used, in which equal variances are not assumed.

For assessment of PCC hypometabolism prevalence in AD, bvFTD and CN, first visual reading was performed. Inter-reader agreement was assessed using Cohen\'s kappa (κ). Agreement was considered poor if κ \< 0.20, satisfactory if 0.21 \< κ \< 0.40, moderate if 0.41 \< κ \< 0.60, good if 0.61 \< κ \< 0.80, and excellent if κ \> 0.81 ([@bb0165]).

Second, the presence of PCC hypometabolism in bvFTD was verified using a SUVr cut-off, which was defined based on the Receiver Operating Characteristic (ROC) separating AD from CN. Findings were validated using the split-half approach, in which the sample was randomly split in half, resulting in a training sample and test sample. In addition, ROC analyses were performed separating AD from bvFTD, and separating bvFTD from CN. Since we aimed to explore specificity of PCC hypometabolism, we chose cut-offs corresponding with a minimum specificity of 90%. Furthermore, ROC curves of cerebellum-normalised SUVr were compared with ROC curves of pons-normalised SUVr with the method by [@bb0050] using MedCalc Statistical Software version 18.2.1 (MedCalc Software bvba, Ostend, Belgium; <https://www.medcalc.org>; 2016).

Relationships between PCC \[^18^F\]FDG SUVr (dependent variable) and all clinical characteristics shown in [Table 1](#t0005){ref-type="table"} (independent variables) were explored using linear regression analyses. Age, sex, diagnostic group and scanner type were included as covariates. In addition, the interaction between diagnosis and clinical variable of interest was introduced into the model.Table 1Cohort characteristics.Table 1n = 136AD\
n = 81bvFTD\
n = 33CN\
n = 22PCC metabolism\[^18^F\]FDG SUVr cerebellum1361.04 ± 0.11[†](#tf0005){ref-type="table-fn"}, [‖](#tf0020){ref-type="table-fn"}1.13 ± 0.15[§](#tf0015){ref-type="table-fn"}1.21 ± 0.12\[^18^F\]FDG SUVr pons1361.50 ± 0.18[†](#tf0005){ref-type="table-fn"}, [‖](#tf0020){ref-type="table-fn"}1.64 ± 0.191.73 ± 0.19  DemographicsAge13663 ± 865 ± 861 ± 8Female13630(37)13(39)6(27)Education1355.2 ± 1.24.6 ± 1.4[§](#tf0015){ref-type="table-fn"}5.6 ± 1.1Duration of complaints1293.3 ± 2.33.9 ± 3.23.3 ± 1.7Age at onset complaints12960 ± 861 ± 757 ± 9  APOE genotypeAPOE e4 positive12545 (56)[§](#tf0015){ref-type="table-fn"}, [‖](#tf0020){ref-type="table-fn"}7 (21)7 (32)  CSFAbeta~1--42~ pg/mL136473 ± 115[†](#tf0005){ref-type="table-fn"}, [‖](#tf0020){ref-type="table-fn"}942 ± 237993 ± 203tau pg/mL136692 ± 401[†](#tf0005){ref-type="table-fn"}, [‖](#tf0020){ref-type="table-fn"}350 ± 199262 ± 141ptau pg/mL13694 ± 2[†](#tf0005){ref-type="table-fn"}, [‖](#tf0020){ref-type="table-fn"}45 ± 1651 ± 30  Neuropsychological compound z-scoresMemory136−0.34 ± 0.73[†](#tf0005){ref-type="table-fn"}, [\#](#tf0030){ref-type="table-fn"}0.03 ± 0.65[†](#tf0005){ref-type="table-fn"}0.88 ± 0.78Language130−0.16 ± 1.05[‡](#tf0010){ref-type="table-fn"}−0.13 ± 0.66[\#](#tf0030){ref-type="table-fn"}0.58 ± 0.71Attention135−0.13 ± 0.73[§](#tf0015){ref-type="table-fn"}−0.00 ± 0.870.36 ± 0.71Visuospatial functioning118−0.22 ± 1.080.21 ± 0.490.28 ± 0.89Executive functioning135−0.14 ± 0.79[†](#tf0005){ref-type="table-fn"}−0.17 ± 0.91[‡](#tf0010){ref-type="table-fn"}0.57 ± 0.74MMSE13523 ± 4[†](#tf0005){ref-type="table-fn"}24 ± 3[†](#tf0005){ref-type="table-fn"}28 ± 3CDR900.8 ± 0.30.8 ± 0.50.6 ± 0.4^⁎^NPI1049.6 ± 8.4[¶](#tf0025){ref-type="table-fn"}19.5 ± 14.616 ± 11^⁎^[^1][^2][^3][^4][^5][^6][^7]

Within the bvFTD group we compared characteristics of patients having normal PCC metabolism with patients having PCC hypometabolism based on visual reading (reader A). First, clinical characteristics were compared between these two subgroups using chi-squared tests, Kruskal-Wallis analyses, or ANOVA. In addition, regression analyses were repeated as described before, replacing the variable diagnostic group by PCC metabolism (normal metabolism versus hypometabolism based on visual reading by reader A) in the model. Statistical significance was set at *p* \< 0.05. Due to the explorative character of our study (exploring associations between PCC metabolism and clinical characteristics), no statistical correction for multiple testing was performed.

3. Results {#s0050}
==========

3.1. Cohort characteristics {#s0055}
---------------------------

Characteristics of the three diagnostic groups are summarised in [Table 1](#t0005){ref-type="table"}.

3.2. Prevalence of PCC hypometabolism {#s0060}
-------------------------------------

[Fig. 1](#f0005){ref-type="fig"} shows example \[^18^F\]FDG PET scans of one subject from each diagnostic group. Using either cerebellum or pons as reference region, PCC SUVr was lower in AD than in bvFTD and CN, with the largest range of values in bvFTD ([Fig. 2](#f0010){ref-type="fig"}). Presence of PCC hypometabolism was assessed with visual reading by two nuclear medicine physicians. Results are shown in [Table 2](#t0010){ref-type="table"} together with corresponding Cohen\'s κ. Inter-reader agreement per subject is indicated by different colours in [Fig. 2](#f0010){ref-type="fig"}.Fig. 1PCC \[^18^F\]FDG uptake visualised in a CN subject (SUVr = 0.948), a bvFTD patient (SUVr = 0.939), and an AD patient (SUVr = 0.768). SUVr were measured using the cerebellum as reference region.Fig. 1Fig. 2Boxplots showing PCC \[^18^F\]FDG SUVr in CN, bvFTD, and AD with cerebellum (left panel) and pons (right panel) as reference region. Colours indicate whether PCC hypometabolism was present (dark blue) or absent (light blue) as rated by both readers. Green colours indicate disagreement between readers regarding PCC metabolism; light green indicates normal metabolism, and dark green indicates hypometabolism as rated by BvB, where DvA rated metabolism the other way around. The dotted line corresponds with a cut-off defined using the ROC separating PCC \[^18^F\]FDG SUVr in AD versus CN.Fig. 2Table 2Presence of PCC hypometabolism based on visual reading.Table 2nReader AreaDer BκAll13684 (62%)85 (63%)0.734CN221 (5%)0 (0%)[a](#tf0035){ref-type="table-fn"}bvFTD3310 (30%)16 (49%)0.509AD8173 (90%)69 (85%)0.546[^8][^9]Table 3Diagnostic accuracy of SUVr for distinguishing between diagnostic groups.Table 3ROC-AUCSUVr cut-offSpecificitySensitivityPositive predictive valueNegative predictive valueCN vs. ADSUVr-c0.86 (0.77--0.96)1.1091 (71--99)70 (59--80)97 (88--99)45 (37--54)SUVr-p0.81 (0.71--0.91)1.5291 (71--99)56 (44--67)96 (86--99)36 (53--72)  CN vs. bvFTDSUVr-c0.66 (0.52--0.81)1.0791 (71--99)42 (25--61)88 (64--97)51 (43--59)SUVr-p0.64 (0.49--0.79)1.5191 (71--99)27 (13--46)82 (52--95)45 (39--52)  bvFTD vs. ADSUVr-c0.68 (0.56--0.80)0.9791 (76--98)23 (15--34)86 (67--95)33 (29--36)SUVr-p0.71 (0.60--0.82)1.3891 (76--98)30 (20--41)89 (72--96)34 (31--39)[^10]Fig. 3Receiver operating characteristic separating PCC \[^18^F\]FDG SUVr in CN versus AD.Fig. 3

Presence of PCC hypometabolism in bvFTD was validated using an \[^18^F\]FDG SUVr cut-off defined by the ROC separating AD from CN. When using cerebellum as reference region, the cut-off was set at 1.10 (area under the curve \[AUC\] = 0.86, specificity = 91%, sensitivity = 70%; [Table 3](#t0015){ref-type="table"}, and [Fig. 3](#f0015){ref-type="fig"}). Based on this cut-off, 42% of bvFTD patients had PCC hypometabolism. When using pons as reference region, the cut-off was set at 1.52 (AUC = 0.81, specificity = 91%, sensitivity = 56%, [Table 3](#t0015){ref-type="table"}, and [Fig. 3](#f0015){ref-type="fig"}). Using this cut-off, 27% of bvFTD patients had PCC hypometabolism. Split-half validation with cerebellum as reference region resulted in a SUVr cut-off at 1.03 (AUC = 0.85, specificity = 92%, sensitivity = 50%) in the training sample, corresponding with 40% of 15 bvFTD patients having PCC hypometabolism in the test sample. Split-half validation with pons as reference region resulted in a SUVr cut-off at 1.39 (AUC = 0.77, specificity = 92%, sensitivity = 19%) in the training sample, corresponding with 13% of 15 bvFTD patients having PCC hypometabolism in the test sample. Additional characteristics of ROC curves separating CN from bvFTD, and bvFTD from AD are shown in [Table 3](#t0015){ref-type="table"} and [Supplementary figure](#ec0005){ref-type="supplementary-material"}. No differences were found when ROC-AUC from pons-normalised data were compared with cerebellum-normalised data using the method by [@bb0050].

3.3. Relationship between PCC metabolism and clinical characteristics in diagnostic groups {#s0065}
------------------------------------------------------------------------------------------

We performed age, sex, and scanner adjusted linear regression analyses to assess associations between PCC \[^18^F\]FDG SUVr and demographics, neuropsychological, and neurobiological characteristics stratified for clinical diagnosis (with CN as reference group). When the cerebellum was used as reference region, there was a significant interaction between clinical diagnosis and age (*p*~interaction~ = 0.007, eta^2^ = 0.125), showing a positive association between PCC metabolism and age in AD (*p*~interaction~ = 0.047, standardized beta \[standardized error; SE\] = 0.010\[0.005\]). A comparable effect was seen between clinical diagnosis and age at onset of complaints (*p*~interaction~ = 0.015, eta^2^ = 0.119), showing a positive association between PCC metabolism and age at onset of complaints in AD as well (*p*~interaction~ = 0.034, standardized beta\[SE\] = 0.011\[0.055\]). Results are shown in [Fig. 4](#f0020){ref-type="fig"}. No associations were found when the pons was used as reference region for PCC \[^18^F\]FDG SUVr.Fig. 4Linear regression analyses showed associations between PCC \[^18^F\]FDG SUVr and age in AD (*p*~interaction~ = 0.047, standardized beta \[SE\] = 0.010\[0.005\]), as well as with age at onset of complaints in AD (*p*~interaction~ = 0.034, standardized beta\[SE\] = 0.011\[0.055\]).Fig. 4

3.4. Characteristics of bvFTD patients with PCC hypometabolism compared with bvFTD patients with normal PCC metabolism {#s0070}
----------------------------------------------------------------------------------------------------------------------

Compared with bvFTD patients with normal PCC metabolism -- as assigned based on visual reading by reader A -- bvFTD patients with PCC hypometabolism had lower PCC \[^18^F\]FDG SUVr (using cerebellum \[*p* = 0.001\] or pons \[*p* = 0.004\] as reference region), and performed worse on the memory domain (*p* = 0.021; data shown in [Table 4](#t0020){ref-type="table"}).Table 4Characteristics of bvFTD patients, divided into subgroups based on absence or presence of PCC hypometabolism.Table 4n = 33Normal PCC metabolism\
n = 23PCC hypo-metabolism\
n = 10PCC metabolism\[^18^F\]FDG SUVr cerebellum331.18 ± 0.121.01 ± 0.14[†](#tf0040){ref-type="table-fn"}\[^18^F\]FDG SUVr pons331.70 ± 0.141.50 ± 0.22[‡](#tf0045){ref-type="table-fn"}  DemographicsAge3363 ± 868 ± 5Female3310 (44)3 (30)Education324.5 ± 1.54.8 ± 1.3Duration of complaints323.5 ± 3.24.8 ± 3.2Age at onset complaints3260 ± 863 ± 5  APOE genotypeAPOE e4 positive3 (13)4 (40)  CSFAbeta~1--42~ pg/mL33924 ± 228982 ± 263tau pg/mL33349 ± 203353 ± 200ptau pg/mL3347 ± 1742 ± 12  Neuropsychological compound z-scoresMemory330.20 ± 0.57−0.36 ± 0.69[§](#tf0050){ref-type="table-fn"}Language33−0.04 ± 0.61−0.34 ± 0.75Attention330.05 ± 0.90−0.12 ± 0.81Visuospatial functioning330.14 ± 0.500.35 ± 0.45Executive functioning33−0.18 ± 0.87−0.17 ± 1.04MMSE3323.8 ± 3.623.3 ± 3.2CDR270.9 ± 0.60.8 ± 0.3NPI2621.9 ± 15.515.0 ± 12.4[^11][^12][^13][^14]

3.5. Relationship between PCC metabolism and clinical characteristics in bvFTD patients {#s0075}
---------------------------------------------------------------------------------------

We performed age, sex, and scanner adjusted linear regression analyses to assess associations between PCC \[^18^F\]FDG SUVr and demographics, neuropsychological, and neurobiological characteristics stratified for presence of PCC hypometabolism based on visual reading (reader A) in bvFTD patients. When the cerebellum was used as reference region, there was a positive association between PCC hypometabolism and visuospatial functioning (*p*~interaction~ = 0.044, eta^2^ = 0.208, standardized beta\[SE\] = 0.163\[0.075\]). When the pons was used as reference region, there was a positive association between PCC hypometabolism and memory (*p*~interaction~ = 0.002, eta^2^ = 0.419, standardized beta\[SE\] = 0.263\[0.073\]), and a negative association with CDR (*p*~interaction~ = 0.042, eta^2^ = 0.264, standardized beta\[SE\] = −0.434\[0.104\]). Results are shown in [Fig. 5](#f0025){ref-type="fig"}.Fig. 5Linear regression analyses showed associations between PCC \[^18^F\]FDG SUVr and visuospatial functioning in bvFTD patients with PCC hypometabolism (*p*~interaction~ = 0.044, eta^2^ = 0.208, standardized beta\[SE\] = 0.163\[0.075\]) using cerebellum as reference region, as well as with memory (*p*~interaction~ = 0.002, eta^2^ = 0.419, standardized beta\[SE\] = 0.263\[0.073\]), and CDR (*p*~interaction~ = 0.042, eta^2^ = 0.264, standardized beta\[SE\] = −0.434\[0.104\]) using the pons as reference region.Fig. 5

4. Discussion {#s0080}
=============

The main finding of this study is that PCC hypometabolism was not restricted to AD, but that it was also present in a substantial part of bvFTD patients based on visual reading and a more data-driven approach. Furthermore, PCC metabolism was positively associated with age and with age at onset of complaints in AD, consistent with an earlier study demonstrating more distinct PCC hypometabolism in early-onset compared with late-onset AD ([@bb0110]). Within bvFTD, presence of PCC hypometabolism based on visual reading was associated with worse memory performance. Screening tests for global cognition and dementia severity (i.e. MMSE and CDR) however did not differ from bvFTD patients with normal PCC metabolism. Linear regression analyses revealed that within bvFTD patients with PCC hypometabolism based on visual reading, lower PCC \[^18^F\]FDG SUVr was associated with worse memory and visuospatial functioning, as well as with higher scores on the CDR (more severe dementia).

Overall, inter-reader agreement was considered good (κ = 0.734). In bvFTD patients only, however, agreement among readers was considered moderate (κ = 0.509), with presence of PCC hypometabolism ranging from 30 to 49%. Lower inter-reader agreement in bvFTD could be the result of heterogeneity of PCC metabolism, illustrated by a large scatter in [Fig. 2](#f0010){ref-type="fig"}, causing increased difficulty in reading. In addition, assignment of PCC hypometabolism depends on metabolism of other brain regions, whereas prominent frontal (or frontotemporal) hypometabolism could increase difficulty or reading in bvFTD. The most experienced reader (reader A) yielded a specificity of 70% for distinguishing AD from bvFTD, comparable with other \[^18^F\]FDG-PET studies distinguishing AD from other neurodegenerative disorders, such as Silverman e.a. (73%; [@bb0130]) and Jagust e.a. (74%; [@bb0065]), however worse than Foster e.a. (86%; [@bb0040]).

Prevalence of PCC hypometabolism in bvFTD varied using the data-driven approach as well, ranging from 27 to 42%. Prevalence of PCC hypometabolism was highest when the cerebellum was used as reference tissue, coinciding a \[^18^F\]FDG SUVr cut-off characterized by higher sensitivity for PCC hypometabolism based on the ROC curve separating AD from CN. Higher ROC classification was found in cerebellum-normalised data compared with pons-normalised data, probably since pons-normalised data has larger scatter, especially in CN subjects and AD patients. Larger scatter in pons-normalised data could be the result of relative better preservation of glucose metabolism in the pons compared with cerebellum in AD ([@bb0095]).

Several studies have investigated functional and molecular brain imaging characteristics in AD and bvFTD, but to the best of our knowledge, this is the first study investigating the prevalence and clinical characteristics of hypometabolism in the PCC in a large sample of AD and bvFTD patients at diagnosis. One previous study has investigated PCC hypometabolism in the heterogeneous entity of frontotemporal lobar degeneration, and found hypometabolism in four out of fourteen patients ([@bb0155]). Another study separated a sample of eight bvFTD patients based on the presence or absence of autonoetic consciousness, a complex function including the self-awareness in episodic memory, and found that the four impaired patients had lower glucose uptake in the PCC than the others ([@bb0005]). Other studies demonstrated presence of PCC hypometabolism in more advanced disease stages in bvFTD ([@bb0010]; [@bb0060]).

A biological explanation for PCC hypometabolism in neurodegenerative diseases might be found in the functional organization of the brain. The PCC is a highly anatomically and functionally connected region in the brain, and an important hub in the default mode network (DMN) ([@bb0020], [@bb0015]; [@bb0115]). AD is characterized by early disruption of the DMN, with prominent involvement of the PCC, whereas bvFTD is most commonly associated with early changes in the salience network ([@bb0125]; [@bb0160]). During disease progression, more brain regions are found to be involved in both AD and bvFTD, suggesting involvement of multiple networks when neurodegeneration progresses. Possibly, involvement of the PCC in bvFTD at diagnosis is associated with further disease progression, supported by our finding that within the subgroup of bvFTD patients with PCC hypometabolism, lower PCC metabolism was associated with worse memory and visuospatial performance, and with greater disease severity based on the CDR score. The suggestion of an association between PCC involvement and further disease severity is consistent with earlier findings ([@bb0010]; [@bb0060]). We found no differences, however, between global measurements for disease severity or duration of complaints at baseline when we compared bvFTD patients with PCC hypometabolism with bvFTD patients with normal PCC metabolism. Another hypothesis could be that bvFTD is a highly heterogeneous disorder, associated with a subgroup of patients characterized by PCC involvement already early in the disease, and associated with memory impairment, worse visuospatial functioning, and more severe dementia when PCC metabolism is lower. An alternative hypothesis could be that local disruption in the frontotemporal cortex affect connected regions such as the PCC in part of the patients ([@bb0020]).

Among the limitations of our study are the relatively small sample sizes, particularly in the CN group. This could have led to less accurate results when the prevalence of PCC metabolism was explored using the PCC \[^18^F\]FDG SUVr to define a quantitative cut-off for PCC hypometabolism. Furthermore, the relative small sample size could have resulted in an underestimation of exploratory analyses investigating PCC metabolism with clinical characteristics.

Our findings may have important clinical implications, as \[^18^F\]FDG PET is used frequently to differentiate between AD and bvFTD, and especially PCC hypometabolism is commonly considered to be specific for AD. In the differential diagnosis of AD, metabolism of the PCC should be interpreted in the context of different biomarkers, including metabolism of other brain regions and -- for example -- amyloid and tau status as well.

In conclusion, PCC hypometabolism was present in almost one third of bvFTD patients and therefore it is not restricted to AD. In AD, younger age and age at onset of complaints was associated with lower PCC metabolism, using CN as reference. In addition, within bvFTD patients with PCC hypometabolism based on visual reading, lower PCC metabolism was associated with worse memory and visuospatial functioning, as well as with higher scores on the CDR (more severe dementia).

The following is the supplementary data related to this article.Supplementary Fig. 1Receiver operating characteristic separating PCC \[^18^F\]FDG SUVr in CN versus bvFTD, and bvFTD versus AD.Supplementary Fig. 1
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[^1]: Data are presented as mean ± standard deviation, or as number (percentage). APOE e4 positive genotype: ≥one e4 alleles. ^⁎^Only available for 10/22 (CDR) or 12/22 (NPI) in CN subjects. Variables with significant differences based on chi-squared tests, Kruskal-Wallis analyses, or ANOVA are indicated as follows.

[^2]: Difference with CN *p* ≤ 0.001.

[^3]: Difference with CN *p* ≤ 0.01.

[^4]: Difference with CN *p* ≤ 0.05.

[^5]: Difference with bvFTD *p* ≤ 0.001.

[^6]: Difference with bvFTD *p* ≤ 0.01.

[^7]: Difference with bvFTD *p* ≤ 0.05.

[^8]: Data are presented in number of patients with PCC hypometabolism (percentage).

[^9]: κ could not be calculated when reading has resulted in zero patients having PCC hypometabolism.

[^10]: Data are presented with 95% confidence intervals. ROC-AUCs were calculated based on continuous SUVr values, with either cerebellum (SUVr-c) or pons (SUVr-p) as reference region. No differences were found when ROC-AUC from pons-normalised data were compared with cerebellum-normalised data using the method by [@bb0050].

[^11]: Assignment of normal PCC metabolism or PCC hypometabolism was based on visual reading by reader A. Data are presented as mean ± standard deviation, or as number (percentage). APOE e4 positive genotype: ≥one e4 alleles. Variables with significant differences on chi-squared tests, Kruskal-Wallis analyses, or ANOVA are indicated as follows.

[^12]: Difference with normal PCC metabolism *p* ≤ 0.001.

[^13]: Difference with normal PCC metabolism *p* ≤ 0.01.

[^14]: Difference with normal PCC metabolism p ≤ 0.05.
